Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Pediatr Hematol Oncol ; 40(1): 22-26, 2018 01.
Article in English | MEDLINE | ID: mdl-28816795

ABSTRACT

BACKGROUND: Antifungal prophylaxis (AFP) is recommended in at-risk hematology-oncology patients. We evaluated the safety of AFP with voriconazole (VRC) in pediatric hematology/oncology patients. MATERIALS AND METHODS: A retrospective study of VRC AFP in children with malignancies hospitalized in all 7 Greek pediatric hematology/oncology centers during 2008 to 2012 was conducted. Patients' demographics, outcome, and adverse event (AE) data were recorded. RESULTS: Four hundred twenty-nine VRC AFP courses in 249 patients (median age 6 y, 55% boys) were studied. The most common underlying diseases were acute lymphoblastic leukemia (51%), non Hodgkin lymphoma (8.6%), and acute myeloid leukemia (7.7%). The median number of VRC courses per patient was 1.7, whereas the median VRC dose was 7 mg/kg (range, 5 to 7 mg/kg) every 12 hours. During the last 2 weeks before AFP, 51% of the patients had received corticosteroids, 43% suffered from severe neutropenia, and 17.3% from mucositis. The median duration of VRC AFP was 17 days (range, 1 to 31 d). A single breakthrough fungemia due to Candida glabrata was recorded. Only 1 patient died due to the underlying disease. The most common AEs reported in 70/429 (16.3%) courses with ≥1 AE were elevated liver enzymes (50%), hypokalemia (24.3%), and ophthalmological disorders (14.3%). The median time of AE onset was 5 days (range, 1 to 21 d). Among 70 AEs reported, 38.5%, 48.4%, and 12.8% were of grade I, II, and III, respectively. CONCLUSIONS: VRC prophylaxis in pediatric hematology/oncology patients appears to be well tolerated.


Subject(s)
Antifungal Agents/therapeutic use , Mycoses/prevention & control , Neoplasms/drug therapy , Premedication/methods , Voriconazole/therapeutic use , Antifungal Agents/adverse effects , Child , Female , Greece/epidemiology , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/drug therapy , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/drug therapy , Male , Mycoses/drug therapy , Neoplasms/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Premedication/adverse effects , Retrospective Studies , Treatment Outcome , Voriconazole/adverse effects
2.
Cancer Nurs ; 34(4): 269-76, 2011.
Article in English | MEDLINE | ID: mdl-21681145

ABSTRACT

BACKGROUND: The increasing survival rate of children with cancer because of more refined treatments makes necessary the investigation of psychological burden for the young patients. OBJECTIVE: The aim of the study was to evaluate the development of psychological problems in children with cancer during the initial 6-month period of intensive treatment. METHODS: This prospective, comparative study was conducted at one of the largest Greek pediatric oncology units in Athens. The sample comprised 132 children with cancer treated during a 30-month period and 100 children with no cancer as control group. Data were collected using the Rutter instruments for parents and teachers. For patients, it was completed by their parents at 1 (T1), 3 (T2), and 6 months (T3) from diagnosis and by teachers at T3. In the control group, the questionnaire was completed by teachers and parents once. RESULTS: The comparison of total Rutter scores for patients at T1, T2, and T3, according to parents' responses, showed statistically significant difference (P < .001). The difference in scores for patients (at T3) and control subjects was also significant according to both parents' (P < .00001) and teachers' (P < .001) responses. Children with leukemia had higher score reduction during treatment (P = .009) compared with the rest. Only age had a marginal impact on score of patients at T1 (R = 0.04). CONCLUSIONS: Based on parental reports, children treated for cancer develop psychological problems during the period of intensive treatment. The development and evolution of these problems depend on their age and type of cancer. IMPLICATIONS FOR PRACTICE: This information can be used for relevant interventions in specific groups.


Subject(s)
Mental Disorders/epidemiology , Neoplasms/psychology , Adolescent , Age Distribution , Case-Control Studies , Child , Child, Preschool , Female , Greece/epidemiology , Humans , Infant , Leukemia/psychology , Leukemia/therapy , Male , Neoplasms/therapy , Prospective Studies , Time Factors
3.
Pediatr Blood Cancer ; 57(2): 345-7, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21438130

ABSTRACT

We report successful bone marrow transplantation in an 11-year-old male with chronic myeloid leukemia from his HLA-identical sibling selected by preimplantation HLA testing. Because collection of cord blood failed, the transplantation was performed when the donor reached the age of 19 months, and sufficient bone marrow could be harvested safely. The patient was BCR/ABL negative at the time of transplantation after complete molecular response to imatinib. Currently, 16 months post-transplantation he is well and in complete molecular remission. This report describes preimplantation HLA-genotyping to deliver a matched sibling donor for successful transplantation of a malignant disorder.


Subject(s)
Bone Marrow Transplantation , HLA Antigens/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Preimplantation Diagnosis , Siblings , Tissue Donors , Child , Female , Graft Survival , Histocompatibility Testing , Humans , Infant , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Male , Pregnancy
4.
J Pediatr Nurs ; 24(5): 415-22, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19782900

ABSTRACT

The purpose of this study was to assess the quality of life of Greek survivors of childhood cancer by addressing the physical, psychological, spiritual, and social dimensions of their functioning. The SF-36 Health Survey and the Quality of Life Questionnaire, which was designed for this study, were used. Survivors' scores on most subscales of SF-36 were similar to those of controls, despite some difficulties in their daily activities. They perceived self as more susceptible to health problems, but also more mature and grounded. Generally, they seem to adapt well and focus on the positive aspects of their cancer experience, which enhances the meaning and quality of their life.


Subject(s)
Attitude to Health , Neoplasms/psychology , Psychology, Adolescent , Quality of Life/psychology , Survivors/psychology , Activities of Daily Living/psychology , Adaptation, Psychological , Adolescent , Case-Control Studies , Chi-Square Distribution , Goals , Greece , Health Surveys , Humans , Mental Health , Nursing Methodology Research , Self Concept , Social Behavior , Spirituality , Surveys and Questionnaires , Young Adult
5.
Pediatr Hematol Oncol ; 25(5): 375-84, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18569839

ABSTRACT

The aim of this study was to explore the complications related to Hickman-Broviac central venous catheters (Hickman-Broviac CVCs) in children with cancer, their incidence, and possible associations of complications and premature removal of CVCs with a number of risk factors. During the study period (1 Jan 2000-31 Dec 2003), 223 CVCs were inserted in 198 children (117 boys, 81 girls) at a mean age of 5.73 years (95% CI 5.19-6.27, SE 0.275). In total, 76 (38.4%) children suffered from solid tumors and 122 (61.6%) from leukemia. The mean follow-up after CVC insertion was 232.5 days (95% CI 214.9-250.2, SE 8.94) for a total of 51,839 catheter-days. A complication occurred in 20.8% of them and in 9.6% the complication led to the removal of the catheter. The most frequent complications were infection (63.9%), obstruction (26.2%), accidental failure (8.2%), and rupture (1.6%). An overall incidence of 1.17 (0.38 and 0.79 for mechanical complication and infection, respectively) per 1000 catheter days for the development of a complication was recorded. Additionally, the study revealed more nonelective removals in cases of leukemia compared to those of solid tumors. Systemic use of CVC does not appear to increase significantly the number of complications, and thus CVC remains an effective and safe tool for the management of childhood malignancies.


Subject(s)
Catheters, Indwelling/adverse effects , Neoplasms/complications , Catheterization, Central Venous/adverse effects , Child , Child, Preschool , Equipment Failure , Female , Humans , Incidence , Infections , Leukemia/complications , Male , Retrospective Studies , Rupture
6.
Support Care Cancer ; 16(1): 29-36, 2008 Jan.
Article in English | MEDLINE | ID: mdl-17562085

ABSTRACT

GOALS OF WORK: The present study aimed to assess the psychosocial well-being of Greek adolescent and young adult survivors of childhood cancer and, in particular, self-esteem, anxiety, coping strategies, and social functioning. PATIENTS AND METHODS: The sample comprised 103 Greek childhood cancer survivors and 135 healthy controls. The Battle Culture-free Self-esteem Inventory (BCSEI), the Spielberger State-Trait Anxiety Inventory (STAI), the Lazarus and Folkman Ways of Coping, and 36-item short-form instruments were used along with The Questionnaire for the Quality of Life. MAIN RESULTS: Survivors scored higher than controls on all STAI subscales, but on State, the difference was statistically significant only for female adults, while on the Trait subscale, for the entire group. Survivors scored lower on Personal and higher on Lie subscale of BCSEI, by comparison to controls. When coping with stressful events, the use of self-blame strategies and wishful thinking were more frequent among controls, while distancing strategies more common among survivors. CONCLUSIONS: The long-term psychological functioning of Greek survivors of childhood cancer is satisfactory, with emotional difficulties, such as increased anxiety and lower self-esteem, receding over time. Survivors experience personal growth and mature through trauma as they develop a positive view of the impact that the cancer experience has upon their life.


Subject(s)
Adaptation, Psychological , Neoplasms/psychology , Quality of Life , Survivors/psychology , Adolescent , Adult , Age Factors , Anxiety/etiology , Anxiety/psychology , Child , Female , Greece , Guilt , Health Status , Humans , Male , Psychiatric Status Rating Scales , Self-Assessment , Sex Factors , Social Adjustment , Stress, Psychological , Time Factors
7.
Pediatr Blood Cancer ; 50(3): 528-32, 2008 Mar.
Article in English | MEDLINE | ID: mdl-17853465

ABSTRACT

BACKGROUND: We prospectively evaluated the immunological status, immune recovery and risk of infection in pediatric ALL patients treated on the BFM 95 protocol. PROCEDURE: Humoral and cellular immunity were evaluated in 72 children with ALL at the end of intensive therapy and values were compared to those at the completion of therapy and 6-monthly. Parameters investigated included lymphocyte subpopulation by flow cytometry, immunoglobulin levels by nephelometry, antibody titers to previous immunizations and delayed hypersensitivity with skin testing. Immune responses were correlated to duration of therapy, CNS radiotherapy, age and sex. RESULTS: Humoral immunity was severely depressed by the end of intensive therapy with low immunoglobulin levels and CD19, improved after therapy cessation. Cellular immune responses were normal at the end of intensive treatment but declined significantly by the end of therapy and both CD4 and CD8 remained low at later evaluation points whereas CD4/CD8 ratio was increasing. Duration of therapy and CNS radiotherapy did not affect the rate of immune recovery whereas female had higher CD19, CD45RO, and IgM and children >7 years had higher CD19 and lower CD16 and CD3DR. Among immunized children, 86.7% maintained protective antibodies to MMR and 63% to polio. Despite impairment of immunity, infections outside the neutropenic periods were common viral illnesses. CONCLUSION: Humoral immunity was depressed in children with ALL at the end of intensive therapy but began to recover after cessation of therapy. In contrast, cellular immunity declined significantly by the end of therapy and remained abnormal for at least 1 year post-therapy.


Subject(s)
Agammaglobulinemia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Leukemia-Lymphoma, Adult T-Cell/immunology , Neutropenia/chemically induced , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/immunology , Adolescent , Antibodies, Viral/blood , Antibody Formation/drug effects , Antigens, CD/analysis , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Child , Child, Preschool , Combined Modality Therapy , Cranial Irradiation/adverse effects , Disease Susceptibility , Female , Humans , Immunity, Cellular/drug effects , Immunocompromised Host , Infant , Infections/epidemiology , Leukemia-Lymphoma, Adult T-Cell/drug therapy , Leukemia-Lymphoma, Adult T-Cell/radiotherapy , Male , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy , Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Prospective Studies , Skin Tests , T-Lymphocyte Subsets/drug effects , T-Lymphocyte Subsets/immunology
8.
Pediatr Hematol Oncol ; 24(8): 631-8, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18092254

ABSTRACT

The authors report on a 14-year-old adolescent boy suffering of Hodgkin disease in remission, who developed autoimmune anemia and thrombopenia. He was treated with high-dose steroids and he developed serious invasive lung aspergillosis, which was treated with antifungal agents and surgical intervention. Children suffering from cancer are prone to develop systemic fungal infections secondary to the severe immunosuppression caused by the disease itself and the antineoplastic therapy. Intravenous antifungal medications and, when feasible, surgery are used for treatment of pulmonary aspergillosis. Factors related to better outcome are early diagnosis, remission of underlying disease, aggressive antifungal therapy, and recovery from neutropenia.


Subject(s)
Amphotericin B/administration & dosage , Anemia/therapy , Antifungal Agents/administration & dosage , Aspergillosis, Allergic Bronchopulmonary/therapy , Hodgkin Disease/therapy , Purpura, Thrombocytopenic, Idiopathic/therapy , Adolescent , Anemia/diagnostic imaging , Anemia/etiology , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Aspergillosis, Allergic Bronchopulmonary/diagnostic imaging , Aspergillosis, Allergic Bronchopulmonary/etiology , Bleomycin/administration & dosage , Etoposide/administration & dosage , Hodgkin Disease/complications , Hodgkin Disease/diagnostic imaging , Humans , Lung/diagnostic imaging , Lung/surgery , Male , Prednisone/administration & dosage , Purpura, Thrombocytopenic, Idiopathic/diagnostic imaging , Purpura, Thrombocytopenic, Idiopathic/etiology , Radiography , Vinblastine/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...